CA
NZ
UK
AU
IND
US
Companies (Nasdaq:COO). Cooper's fiscal second quarter, covering the three months and reported on 4 June, was two stories filed under one headline. Revenue reached $1.082 billion, up 8% reported and 5% organically, and non-GAAPDiluted Earnings per Shareof $1.21 rose 26% year over year on …
Thermo Fisher Scientific (NYSE:TMO) reported second-quarter 2026 revenue of $11.99 billion on 23 July, up 10% from a year earlier, and raised its full-year outlook. AdjustedEarningsof $6.03 a share cleared a consensus of roughly $5.71, and revenue beat an $11.7 billion estimate. Shares responded …
United Therapeutics (Nasdaq:UTHR) reports second-quarter results before the open, and the setup is unusually contradictory. First-quarter revenue of $781.5 million was down 2% from $794.4 million a year earlier,Net Incomefell 15% to $274.9 million, andDiluted Earnings per Sharedropped to $5.82 from $6.63. Those are …
Incorporated (Nasdaq:VRTX). At last closing, Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for $85.00 a share in cash, about $10.0 billion in equity value, or roughly $8.8 billion net of Crinetics' estimated cash. It is the largest acquisition in Vertex's history, and it buys …
Viatris (Nasdaq:VTRS) reports second-quarter results, and it arrives at that date as a materially different stock from the one investors abandoned a year ago. Shares closed at $17.56 on 31 July, down 1.13% on the session, but up about 95% over 52 weeks against …
Regeneron (Nasdaq:REGN) reported on 30 July that second-quarter revenue rose 17% to $4.29 billion and non-GAAP earnings per share climbed 11% to $14.29. Both comfortably cleared consensus of roughly $3.82 billion and $10.26, according to Reuters. Chief executive Leonard Schleifer described the quarter as …
ResMed (NYSE:RMD) agreed to sell MatrixCare, the post-acute and senior-living software business inside its Residential Care Software segment, to private equity firm Frazier Healthcare Partners. Chief executive Mick Farrell described the decision as "disciplinedPortfolio Management," aimed at areas with the "greatest opportunity for sleep …
The FDA accepted Revolution Medicines (Nasdaq:RVMD)' new drug application for daraxonrasib in previously treated metastatic pancreatic ductal adenocarcinoma at last closing. It is the Redwood City company's first application forMarketingapproval, filed under the FDA Commissioner's National Priority Voucher pilot program, a designation daraxonrasib received …
Revvity (NYSE:RVTY) closed at $112.52 at last closing, down 0.90% on volume of roughly 1.2 million shares. On its own the move is noise. Its timing is not: the Waltham, Massachusetts company reports second-quarter 2026 results before the open on Tuesday 4 August, with …
Roivant Sciences (Nasdaq:ROIV) closed at $33.91, down 1.77% on the day, according to aggregated market data. The slip is noise against a stock that has risen roughly 197% over the past year, but it comes at an unusually loaded moment. Priovant, Roivant's inflammationSubsidiary, awaits …
Please wait processing your request...